Lexeo Therapeutics, Inc.
NASDAQ · us_market
No AI insight generated yet for this ticker.
Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy. The company is also developing LX2022, a gene therapy candidate, which is in preclinical trial to deliver a functional TNNI3 gene to myocardial cells to treat a distinct form of hypertrophic cardiomyopathy. In addition, it is developing LX1001, LX1020, and LX1021, an AAVrh10-based gene therapy candidate, which has completed phase 1/2 clinical trial for the treatment of APOE4-associated Alzheimer's disease. The company has a license agreement with Cornell University to conduct the Phase 1/2 clinical trial of LX1001, as well as support the development of the LX1004 program; a research collaboration agreement with Cornell University to conduct preclinical research to develop the licensed technology; and third license agreement which obtained certain rights for FA cardiomyopathy, including rights to current and future clinical data from an ongoing Cornell University investigator-initiated Phase 1A trial of a gene therapy candidate. The company was founded in 2017 and is headquartered in New York, New York.
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| StateStreet | passive | 3.57M | $20.48M | 0.00% | Added+11.9% | 2026-03-31 |
| Citadel | multi-strat | 1.68M | $9.65M | 0.01% | Trimmed-11.3% | 2026-03-31 |
| TwoSigma | quant | 181.7K | $1.04M | 0.00% | Trimmed-54.6% | 2026-03-31 |
| Wellington | fundamental | 172.7K | $991.32K | 0.00% | Added+107.5% | 2026-03-31 |
| DEShaw | quant | 30.5K | $174.94K | 0.00% | Trimmed-93.7% | 2026-03-31 |
| FidelityFMR | fundamental | 24.4K | $139.99K | 0.00% | Added+82.2% | 2026-03-31 |
| TRowePrice | fundamental | 43.1K | $248 | 0.00% | Added+27.3% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-13upcoming | -0.28 | — | — |
| 2026-05-11 | -0.30 | -0.25 | +16.20% |
| 2026-03-30 | -0.30 | -0.27 | +10.47% |
| 2025-11-05 | -0.46 | -0.33 | +28.26% |
| 2025-08-14 | -0.66 | -0.68 | -2.45% |
| 2025-05-12 | -0.77 | -0.99 | -27.91% |
| 2025-03-24 | -0.78 | -0.78 | -1.01% |
| 2024-11-13 | -0.67 | -0.89 | -33.21% |
| 2024-08-12 | -0.69 | -0.64 | +7.20% |
| 2024-05-09 | -0.79 | -0.77 | +2.53% |
| 2023-12-11 | -3.02 | -1.20 | +60.20% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| LXEO | -10.92% | -27.30% | -48.24% | +88.97% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | -13.89% | -22.66% | -44.79% | +76.28% |